Ex1 Flashcards
corticosteroids MOA
inhibit phospholipase A2
- decr leukotrines
- decr prostaglandins
inhibit Th2 cells
- decr IL4/IL5
corticosteroids SE
oral thrush (inhaled)
adrenal supression (systemic)
incr infections
slow growth
bruising
hyperglycemia
weight gain
mast cell stabilizer MOA
inhibit prostaglandin/leukotrine release
mast cell stabilizer SE
mild anti-inflammatory
inhaled cortocosteroids: indication
chronic asthma/COPD
oral corticosteroids: indication
severe chronic asthma
IV corticosteroids: indication
acute asthma attack
mast cell stabilizer indication
mild-mod asthma
leukotrine R antagonist MOA
block leuk-R
- decr sm muscle contraction
- decr mucus
- decr inflammation
leuk R antagonist SE
headache
rash
leuk R antagonost indication
add-on therapy to corticosteroids for chronic asthma
leuk synthesis inhibitor MOA
inhibits 5-lipoxygenase
leuk synth inhibitor SE
hepatoxicity
leuk synth inhibitor indication
exercise/allergy-induced asthma
anti-IgE antibody MOA
binds IgE antibodies
- decr mast cell activation
anti-IgE antibody SE
incr infections
injection site pain
$$$$
anti-IgE antibody indications
last-line defense for allergic asthma
b2 agonist MOA
promotes B2 receptors
- incr adenyl cyclase
- incr cAMP
- incr relaxation
stabilizes mast cells
SABA indication
acute asthma
exercise bronchospasm
SABA SE
incr sympathetics
LABA indication
mx therapy as combo drug
LABA SE
significant incr sympathetics
arrythmias
HF
muscarinic antagnoist MOA
bind M3R
- decr sm muscle contraction
muscarinic antagonist SE
incr sympatheticsm
muscarinic antagonist CI
narrow angle glaucoma
muscarinic antagnoist indications
COPD additive w/LABA
methylxanthines MOA
inhibit PDE
- sm muscle relaxation
decr adenosine
- sm muscle relaxation
- vasoconstriction
methylxanthines SE
incr HR
arrythmia
insomnia
N/V
seizure
narrow therapeutic window
methylxanthines therapeutic window
narrow (5-15 mcg/mL)
methylxanthines CI
fluoxetine
ciproflaxin
(block CYP450 - inhibits metabolism)
intermittent asthma mgmt
SABA
mild asthma mgmt
low dose ICS
mod asthma mgmt
low dose ICS + LABA
OR
med dose ICS
severe asthma (4) mgmt
med dose ICS + LABA
severe asthma (5) mgmt
high dose ICS + LABA
optional omalizumab
severe asthma (6) mgmt
high dose ICS + LABA + corticosteroids
optional omalizumab
mild/intermittent COPD mgmt
SABA + SAMA
frequent CPOD (FEV1<60%) mgmt
LABA + LAMA
loading dose is dependent on
volume of distribution
LD equation
LD = tgt conc * Vd
when is LD required
if drug has long half life
(slow onset)
mx dose is dependent on
drug clearance
what physiology can cause abnormal drug clearance
major impairement to kidney, liver, heart
how are drugs predominantely excreted
via kidney/liver
excreted drug characteristics
water soluble
polarized
small size
free (not bound)
lipid soluble drugs require
hepatic metabolism to incr water solubility
drug filtration factos
renal BF
GFR
plasma protein binding
GA ____ renal BF by _____%
GA decreases renal BF by 50%
routine labs to assess kidney function
BUN
serum Cr
GFR
urine albumin
normal BUN
10-20 mg/dL
normal serum Cr
0.6-1.3 mg/dL
normal GFR
110-140 mL/min
normal urine albumin
<150 mg/day
specialized labs for kidney function
urine specific gravity
urine osmolarity
urine Na+
factors that influence lab interpretation
dehydration
protein intake
GI bleed
catabolism
adv age
sk muscle mass
timing of measurement
G1
normal/high
G2
mild decrease
G3a
mild-mod decrease
G3b
mod-severe decrease
G4
severe decrease
G5
kidney failure
what GFR categories indicate CKD
G3a-G5
A1
normal/mild albuminuria
A2
moderate albuminuria
A3
severe albuminuria
which albuminuria category indicates nephrotic syndrome
A3